Company intelligence / Profile preview

Qlibrium

Woburn, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Qlibrium has developed the Evopump, a wearable on-body drug delivery system utilizing electrochemical and microfluidic technology. The company has completed proof-of-concept prototypes, initiated human factors studies with positive feedback, and validated the technology's robustness through International Space Station experiments. Qlibrium has also established co-development collaborations with major pharmaceutical firms for its platform targeting indications like diabetes, oncology, autoimmune conditions, and in-vitro fertilization.

Therapeutic areas: OncologyEndocrinologyImmunologyWomen's Health
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

Johnson & JohnsonBoeingNASAJDRF InternationalAnalog DevicesMultiple unnamed global pharmaceutical companies

Beyond the preview

Go deeper on Qlibrium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qlibrium.

Explore the full profile